Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03376737
Other study ID # AHEAD-HNP012
Secondary ID
Status Recruiting
Phase Phase 2
First received December 13, 2017
Last updated December 13, 2017
Start date October 12, 2017
Est. completion date June 2019

Study information

Verified date December 2017
Source Henan Cancer Hospital
Contact Guowei Zhang
Phone 13949109625
Email dugu4986@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to confirm the safety and efficacy of Apatinib plus Pemetrexed as the Maintenance Therapy in Advanced Lung Adenocarcinoma.


Description:

Lung adenocarcinoma is the most common NSCLC,most patient were diagnosed to advanced stage. Maintenance treatment is the continuation of treatment after first-line treatment and before the disease progresses. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients. We designed the study to explore the possibility of apatinib for maintenance.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date June 2019
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically or cytologically confirmed of lung adenocarcinoma, EGFR wild-type or known drug-resistant mutation, stage IV or irradiative stage IIIB.

2. Age = 18 years;

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1;

4. Patients had previously received at least 4 cycles of first-line, double chemotherapy and had no disease progression at baseline screening compared with baseline imaging prior to first-line chemotherapy;

5. Adequate hepatic, renal, heart, and hematologic functions: ANC = 1.5×109/L, PLT = 100×109/L, HB = 90 g/L, TBIL = 1.5×ULN, ALT or AST = 2.5×ULN (or = 5×ULN in patients with liver metastases), Serum Cr = 1×ULN, Cr clearance = 45 mL/min;

Exclusion Criteria:

1. Active brain metastases, meningococcal meningitis, patients with spinal cord compression, or imaging at CT or MRI examination revealed brain or pia mater disease(Patients who have completed treatment and whose symptoms are stable in the first 21 days of randomization may be enrolled in the study but may be diagnosed as having no intracerebral hemorrhage by MRI, CT or venography);

2. Imaging (CT or MRI) showed that the tumor lesions were = 5 mm from the major vessels or there was a central tumor invading local macrovascular;

3. Imaging (CT or MRI) showed significant cavitary or necrotic lung tumors, uncontrollable hypertension (systolic BP =140 mmHg or diastolic BP =90 mmHg, despite optimal medical therapy), grade II The above myocardial ischemia or myocardial infarction, poor control of arrhythmia (including QTc interval male = 450 ms, female = 470 ms); NYHA standards, ? ~ ? grade cardiac insufficiency, or cardiac ultrasound examination prompted left ventricular ejection Score (LVEF) <50%;

4. Coagulation dysfunction (INR> 1.5, PT> ULN +4s or APTT> 1.5 ULN), with bleeding tendency or ongoing thrombolysis or anti-blood coagulation treatment;Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or the like;

5. Patients who had obvious hemoptysis within 2 months before screening, or experienced daily hemoptysis with a volume more than half a tea spoon (2.5ml) or above;

6. Patients who experienced bleeding symptoms of clinical significance within 3 months before screening, or with confirmed bleeding tendency such as hemorrhage of digestive tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and above, or vasculitis, etc.

7. Patients who manifested arterial/venous thrombus events, e.g. cerebrovascular accident (Including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening(Such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism and so on);

8. Patients whose routine urine tests indicate that urine protein = ++ or verifies that the 24-h urine protein quantitation = 1.0 g;

9. Confirmed ALK gene fusion;

10. Anti-angiogenic drugs were used during first-line chemotherapy?

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apatinib
Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)

Locations

Country Name City State
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (2)

Lead Sponsor Collaborator
Henan Cancer Hospital Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (PFS) From date of randomization until the date of first documented progression or date of death from any cause up to 2 year
Secondary Overall survival(OS) From date of randomization until the date of death from any cause up to 2 year
Secondary Objective Response Rate (ORR) From date of randomization until the date of death from any cause up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02898857 - Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma N/A
Completed NCT02127359 - Whole-Exome Sequencing (WES) of Cancer Patients
Recruiting NCT01249066 - Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma N/A
Not yet recruiting NCT04482829 - TCM in the Treatment of Lung Adenocarcinoma N/A
Recruiting NCT04929041 - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Phase 2/Phase 3
Terminated NCT04691375 - A Study of PY314 in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT02621333 - Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma Phase 2
Active, not recruiting NCT02282267 - Blood Detection of EGFR Mutation For Iressa Treatment N/A
Not yet recruiting NCT01942629 - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas N/A
Recruiting NCT01482585 - Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy N/A
Recruiting NCT05537922 - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Recruiting NCT04937283 - Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm N/A
Recruiting NCT06255197 - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Completed NCT02093000 - A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma N/A
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Terminated NCT04682431 - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05736991 - Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Enrolling by invitation NCT05136014 - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Recruiting NCT05266846 - Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK Phase 2